LECTURE SIX

Fungal infections are on the rise (especially in the immunocompromised), mortality rates are high and new antifungal drugs are urgently required. This lecture highlights genomic approaches to target identification and the use of co-drugs

If you are having trouble viewing the embedded video, go to: https://youtu.be/rIPdweQv5ss

Antifungals

© Jem Stach - Material intended solely for students enrolled @ Newcastle University - MSc Industrial and Commercial Biotechnology. jem.stach@newcastle.ac.uk

JS

Directed reading

Forum.html
Home.html

Sanglard D. Integrated antifungal drug discovery in Candida albicans.

Nat Biotechnol. 2001 Mar;19(3):212-3.

De Backer MD, Nelissen B, Logghe M et al. An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans. Nat Biotechnol. 2001 Mar;19(3):235-41.

Zhang L, Yan K, Zhang Y. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4606-11. Epub 2007 Mar 5.

Kitamura A. Discovery and characterization of ß-1,6-glucan inhibitors. Expert Opin Drug Discov. 2010 Aug;5(8):739-49. doi: 10.1517/17460441.2010.498472. Epub 2010 Jun 18.

Nosanchuk JD. Current status and future of antifungal therapy for systemic mycoses. Recent Pat Antiinfect Drug Discov. 2006 Jan;1(1):75-84.

*error in slide video at 35:16 - ERG11, NCP1, PDR17 & CDR1 have positive Z scores, ERG6 has a negative Z score

Extra material associated with this lecture can be found in the Reading section